Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster ...

Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster ...

In contrast to an oral presentation, a “poster” is a visual representation of the research project that must convey the essence of your message. In effect, it “talks” for the researcher. The poster ...

Effective posters stand out because they convey their main message almost instantly, and then seduce participants to stay longer and learn more. Much more than oral presentations, posters are about ...

Illumina (ILMN) will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic ...

Five Agendia abstracts have been accepted, including two poster spotlight presentations and one late-breaking poster ...

including five accepted abstracts for poster presentation and participation in the workshop “From Data to Decisions: The Potential of RWE Transportability in Healthcare Decision Making.” ...

All Environmental Studies majors participate in public poster presentations as part of the thesis process. A poster session is organized for Wednesday in the last week of the fall and winter semesters ...

TruSight Oncology portfolio enables clinical research and in-vitro diagnostic CGP solutions ...

- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS Initial data from the dose escalation phase using a July 15, 2024 data cutoff date indicate that ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 ...

NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San ...